About us
Syngulon is a synthetic biology startup developing original genetic technologies using bacteriocins to improve microbial fermentation.
Our team of scientists works in different academic laboratories and our R&D programs involve partners from Belgium, Brazil, France, Germany, The Netherlands, and the UK. We think of ourselves as a “Startup in the Labs”, meaning that we work directly in the labs of our academic partners.
The members of our Scientific Advisory Board are active in Belgium, France and the USA.
Bacteriocins
Bacteriocins are ribosomally-produced, genetically encoded antimicrobial peptides produced by a wide variety of microorganisms.
The history of bacteriocins begins with André Gratia in Belgium in 1925, concurrent with the discovery of antibiotics and bacteriophages.
With synthetic biology, it is now possible to revisit the code of bacteriocins in order to modify the spectrum of action and even make entirely new bacteriocins.
In Bacteriocins vs Antibiotics and Bacteriophages, the advantages of bacteriocins are described in the context of rising AMR (Antimicrobial resistance).
Syngulon is building PARAGEN, a collection of natural and synthetic bacteriocins.
Technologies
We harness the unique properties of bacteriocins to engineer innovative genetic technologies that address some of the most pressing challenges in biotechnology and health.
Our technology portfolio is structured around three core applications:
- Antibiotic-free genetic selection – sustainable alternatives to antibiotic resistance markers for recombinant protein production.
- Precision contamination control – advanced systems that actively protect industrial bioprocesses from microbial contamination.
- Next-generation antimicrobials – novel bacteriocin-based molecules offering targeted strategies against resistant pathogens.
You must be logged in to post a comment.